Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ExpressGraft-C9T1
- Development stage
- Discontinued
- Lead developer
- Mallinckrodt
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Topical
01
Overview
ExpressGraft-C9T1 is a genetically engineered human skin substitute developed as a cell therapy for the treatment of diabetic foot ulcers. The product consists of human skin tissue that has been genetically modified to express elevated levels of the human cathelicidin host defense peptide, which is believed to enhance antimicrobial activity and promote wound healing. It was developed by Stratatech, a subsidiary of Mallinckrodt. Clinical trials have focused on assessing its safety and tolerability in patients with diabetic foot ulcers who have not responded to standard treatments[1][2][3][4][5].
- Brand names
- ExpressGraft-C9T1ExpressGraft-C-9T1ExpressGraft-C 9T1
- Other names
- ExpressGraft-C9T1 skin tissueExpressGraft-C-9T1 skin tissueExpressGraft-C 9T1 skin tissue
02
Targets
P2RX7 (P2X purinoceptor 7)FPR2 (Formyl peptide receptor type 2)TLR (Toll-like receptors)
Beyond the preview
Go deeper on ExpressGraft-C9T1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExpressGraft-C9T1.